Target Product Profiles for Alzheimer’s Disease Prevention Therapies

An international group of experts has developed target product profiles for therapies intended to delay or prevent the onset of clinical symptoms in Alzheimer’s disease. The framework, published April 3, 2026, in Nature Medicine, aims to accelerate the development of therapeutic interventions and provide stakeholders with clear benchmarks for evaluation.

As of April 3, 2026, there are no approved therapies available to prevent or delay the onset of Alzheimer’s disease in individuals who are considered at risk. This includes populations with elevated biomarkers who do not yet exhibit clinical symptoms.

To address this gap, the Global CEO Initiative on Alzheimer’s Disease convened the expert group to establish these profiles. The initiative focuses on creating a foundational framework that guides researchers, regulators, and patients in assessing emerging therapies.

Understanding Target Product Profiles

A Target Product Profile, or TPP, is a tool used to indicate the specific characteristics required in a medical product to meet a particular health need. According to the World Health Organization, a TPP typically outlines both minimal and optimal characteristics for a product.

These profiles are designed to improve the efficiency of developing new products, particularly for global health threats or diseases where there may be limited market incentives for research, and development.

In the context of Alzheimer’s disease, these TPPs outline the minimum and preferred characteristics that a preventive therapy should possess. This includes detailed specifications regarding intended use, the target populations for the treatment, safety expectations, and efficacy benchmarks.

Strategic Importance for Clinical Trials

The development of these profiles comes at a critical juncture for neuroscientific research. Multiple candidate interventions are currently being evaluated in clinical trials specifically designed for at-risk or asymptomatic populations.

Data from these clinical trials are expected to be available within one to two years, placing the window of results between April 2027 and April 2028.

The availability of this data underscores the necessity for stakeholder alignment. Without agreed-upon benchmarks, determining which populations are most appropriate for treatment and which criteria should guide regulatory decision-making remains a challenge.

Guidance for Stakeholders and Regulators

The target product profiles serve as a roadmap for various entities involved in the drug development lifecycle. For researchers, the profiles provide clear goals for efficacy and safety that a new drug must meet to be considered viable.

For regulators, these benchmarks provide a standardized basis for evaluating the clinical meaningfulness of a therapy’s results. This alignment is intended to streamline the approval process for therapies that can demonstrably delay the onset of symptomatic Alzheimer’s disease.

Patients and healthcare providers also benefit from these profiles by having a clearer understanding of what constitutes an acceptable or preferred outcome for preventive treatment.

By establishing these minimum and preferred characteristics, the Global CEO Initiative on Alzheimer’s Disease aims to reduce ambiguity in the development process and ensure that future therapies are both safe and clinically effective for the intended populations.